Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics (PLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Protalix (PLX) Reports Q3 Loss, Tops Revenue Estimates

Protalix (PLX) delivered earnings and revenue surprises of 50.00% and 22.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 0.21 (-4.50%)
Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 0.21 (-4.50%)
Protalix Completes Enrollment in Third Fabry Disease Study

Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.

PFE : 36.97 (+0.11%)
SNY : 46.05 (+0.41%)
PLX : 0.21 (-4.50%)
ACOR : 1.98 (-9.59%)
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX--102) for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins including a late-stage clinical...

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.21 (-4.50%)
Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Shlomo Yanai has resigned from the Company's Board of Directors for personal reasons, effective today. Mr. Yanai has served...

PLX : 0.21 (-4.50%)
Protalix (PLX) Reports Q2 Loss, Tops Revenue Estimates

Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 4.23%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Eyal Rubin has been appointed to serve as the Company's new Senior Vice President and Chief Financial Officer, effective...

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), or Protalix, and Chiesi Farmaceutici S.p.A, an international research-focused healthcare Group, or Chiesi, today announced that, following...

PLX : 0.21 (-4.50%)
Protalix (PLX) Reports Q1 Loss, Tops Revenue Estimates

Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 2.85%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.21 (-4.50%)
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?

Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.

INO : 2.44 (-0.41%)
RARE : 37.08 (-1.12%)
AMGN : 221.31 (+0.28%)
PLX : 0.21 (-4.50%)
Research Report Identifies TTM Technologies, Zumiez, Global Net Lease, Catabasis Pharmaceuticals, BioPharmX, and Protalix BioTherapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TTM Technologies, Inc. (NASDAQ:TTMI),...

TTMI : 12.82 (-0.70%)
ZUMZ : 30.74 (+0.26%)
GNL : 19.36 (unch)
CATB : 5.45 (+1.87%)
BPMX : 0.26 (-6.61%)
PLX : 0.21 (-4.50%)
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?

Investors need to pay close attention to Protalix (PLX) stock based on the movements in the options market lately.

PLX : 0.21 (-4.50%)
Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.21 (-4.50%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -0.45 , AIZ +1.53 , SBAC -2.23 , SO +0.22 , WELL -0.82
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar